Sekisui Diagnostics Enters Strategic Alliance with Mesa Biotech Inc. for Molecular POC Testing System
Sekisui Diagnostics becomes exclusive distributor for Mesa Biotech products in the U.S. and Canada
Strategic alliance expands Sekisui Diagnostics’ portfolio and facilitates entry into the molecular point-of-care (POC) market starting with Flu A/Flu B test (pending FDA clearance) followed by additional upper respiratory infectious disease assays
Mesa Biotech products will have immediate access to established distribution into North America markets due to Sekisui’s market strength and strong reputation among healthcare providers
LEXINGTON, MA December 5, 2017 — Today, Sekisui Diagnostics and Mesa Biotech Inc. announce a strategic alliance, to distribute the Mesa Biotech POC molecular system for Flu A/Flu B. Sekisui Diagnostics will assume exclusive distribution of the Mesa Biotech POC system in the U.S. and Canada, pending FDA clearance.
The Mesa Biotech molecular dock and test cassette system provides physicians with rapid infectious disease diagnosis at the point of care with increased sensitivity and specificity over most rapid tests currently on the market by using nucleic acid PCR (polymerase chain reaction) amplification technology. The first test cassette will test for Flu A/Flu B with additional tests to be added over time.
“Sekisui Diagnostics is pleased to announce our new relationship with Mesa Biotech which will complement our existing rapid test portfolio,” said Robert Schruender, President and COO of Sekisui Diagnostics. “This system is highly compatible with our business channels and relationships with distributors. It also offers the potential to strengthen our flu portfolio in the mid-to-long term by offering physicians the simplicity, convenience and procedural familiarity of traditional POC rapid immunoassays, while providing the superior sensitivity, specificity and information content of laboratory-based PCR testing.”
“We are extremely excited to partner with Sekisui Diagnostics for the commercialization of Mesa Biotech’s point of care PCR platform in North America,” said Dr. Hong Cai, co-founder and CEO of Mesa Biotech. “Our PCR platform solution and pipeline coupled with Sekisui’s Diagnostics commercial and supply chain expertise as well as their unparalleled field sales relationships brings tremendous synergy opportunities for both organizations.”
About Sekisui Diagnostics
Sekisui Diagnostics is a global diagnostics company committed to improving patient’s lives by providing innovative medical diagnostics to physicians and laboratories through a global commercial network. Product lines include clinical chemistry and coagulation systems, reagents, point-of-care systems and rapid tests, as well as enzymes and specialty bio-chemicals. For more information visit http://www.sekisuidiagnostics.com.
About Mesa Biotech Inc.
Mesa Biotech designs, develops and manufactures next generation molecular diagnostic tests, bringing the superior diagnostic performance of nucleic acid PCR amplification to the point-of-care (POC). Mesa Biotech’s System consists of a portable, palm-sized dock and a disposable, assay-specific test cassette. This patented system will allow healthcare professionals to access actionable, laboratory-quality results at the POC with greater sensitivity and specificity than current infectious disease rapid immunodiagnostic tests. Mesa Biotech’s technology development has been funded to date by a series of grants and private equity investments. For more information visit http://www.mesabiotech.com.
Sekisui Diagnostics Media:
Lisa Turner, +1 (858) 777-2660
Mesa Biotech Media:
Joleen Schultz, +1 (760) 271-8150